Flagship · Weekly Brief

Macro rationale

Live macro digest reads neutral with extension override binding: QQQ +17.98% over 200d and wRSI 75.8 (SPY 71.6) confirm positioning is stretched, even as VIX 17.01 (-7.7% vs 200d) and HY OAS 2.72 signal complacency. The Gemini brief calls for risk_off at 25% cash, but live signal wins — Hormuz blockade is live (~27% seaborne crude disrupted, Brent $110+), April CPI re-accelerated to 3.8%, ISM Services Prices Paid stuck at cycle-high 70.7, and the Warsh Fed transition (May 15) has hawkish-balance-sheet implications with futures pricing <3% chance of a 2026 cut. 10Y Treasury at 4.622% mechanically discounts long-duration cash flows. Cash holds at neutral ceiling (15%) because the brief's tilt toward physical-layer energy/defense and away from duration-heavy biology and pure compute multiple-expansion is exactly the rotation the book needs — better to deploy into hedges and the named-flow mid-caps than sit in cash. Tail-risk hedges go max: CCJ (uranium producer), MP (rare-earth producer with DoD as largest shareholder), and SCCO (Mexican copper) — three commodity-producer slots vs §5.3 minimum of two.

Thesis

Six broken-thesis closes invoking unlock path B (positionBriefer verdict='broken'): CEG, VST, NOC, RTX, TMO, MRK. CEG and VST already trimmed to stubs; NOC (Sentinel margin breach, score 44), RTX (GTF overhang, score 56), TMO (Third Point full exit + bioprocess weakness, score 50), and MRK (Keytruda LOE bridge inadequate, score 53) all breach the 60-score floor with named invalidation triggers active. Capital redeploys into the brief's physical-layer thesis: open KTOS ($1.45B DoD hypersonic IDIQ), TLN (AWS 1,920 MW PPA through 2042), BE (Brookfield $5B AI DC fuel-cell partnership + Oracle deal), MP (DoD ~15% shareholder, 10-yr NdPr floor + magnet offtake), AVAV (Replicator drone pure-play per brief §7.1), HEI (defense aftermarket compounder), MU (memory infrastructure bottleneck — haiku flagged narrative shift to memory), ARGX (Belgian biology with intact pipeline). Add to TSM (only intact compute name, Jensen's $150B/yr Taiwan commitment) and CCJ (uranium anchor). Trim drift on NVDA, ASML, AVGO, NVO, LLY. Preserve VRTX as biology quality anchor. 18 positions, 15% cash, hedge slots maxed (CCJ, MP, SCCO).

Reflection

Closing 6 broken-thesis names and rotating proceeds into named-flow mid-caps (KTOS, TLN, BE, MP, AVAV) — the brief's physical-layer thesis maps cleanly to specific signed contracts and DoD equity stak

The book has been sitting on six positions where the briefer verdict has been 'broken' for weeks and I kept residual weights as if a recovery would come — that was wrong. When Third Point fully exits TMO and CEG, and Argus cuts CEG by 18% on a utility re-rate, that's the named-funder reversal I'm supposed to act on. The mid-cap displacement bias finally has a clean expression: KTOS/TLN/BE/MP all carry named multi-billion contracts or DoD equity stakes that out-clear several mega-caps on conviction-per-dollar. Anchor list update: VRTX, TSM, CCJ remain anchors; LLY downshifts to satellite given

Positions (18)

• NVDANVIDIAcompute

  trim8.51%-0.54pp72
  flow softeningconf

  Funder

  Hyperscaler 2026 capex still anchored on Blackwell/H200: MSFT $190B, AMZN $200B, GOOGL $180-190B, META $125-145B — combined ~$725B AI capex per brief §5.1. Stargate $500B JV NVDA-hardware anchored. Norway GPFG and GIC additions through 2024 13F cycle still in place; CHIPS-adjacent funding flows intact.

  Unwind

  Hyperscaler capex guide cuts >15% in FY27 prelims, OR sovereign 13F holders (GPFG/GIC) trim >25%, OR ASIC/custom-silicon revenue at AMZN/META/GOOG visibly displaces NVDA on next earnings cycle. Score sub-65 with weight still drifted above entry triggers further trim.

  Catalyst

  GTC June updates; FY26 hyperscaler capex re-guides through Q2 earnings (AMZN/MSFT/GOOG/META end-July)

• TSMTaiwan Semiconductor Manufacturingcompute

  hold8.51%83
  flow acceleratingconf

  Funder

  Only intact compute name in book (score 83, drift +1). Jensen announced $150B/yr Taiwan AI hub investment validating leading-edge node monopoly. CHIPS Act $6.6B Arizona disbursement locked. NVDA/AMD/AAPL/AVGO leading-edge silicon flows exclusively through TSMC. FY26 guidance raised >30%. Taiwan sovereign de facto backstop.

  Unwind

  Sub-2nm yield slip vs Intel/Samsung that breaks gross margin >50% floor, OR major China escalation breaching the Strait, OR NVDA/AAPL multi-quarter sourcing diversification announcement.

  Catalyst

  July monthly revenue; Q2 earnings (mid-July) with 2nm ramp commentary

• ASMLASML Holdingcompute

  trim2.84%-2.40pp64
  flow softeningconf

  Funder

  EUV monopoly intact; Coatue added in Q1 affirming thesis. Norway GPFG holds. ASML 2030 guidance anchors long-cycle thesis. TSMC/Samsung/SMIC 2025-27 EUV orderbook still backstops cash flow.

  Unwind

  China homegrown EUV alternative achieving high-NA equivalent capability OR EU/US export-control regime tightening further to gate sales OR book-to-bill <1.0 for two consecutive quarters. Haiku flagged 3 separate items on Chinese EUV substitution effort — watch closely.

  Catalyst

  Q2 bookings print (mid-July) — must show book-to-bill recovery

• AVGOBroadcomcompute

  trim3.31%-1.36pp61
  flow softeningconf

  Funder

  Hyperscaler custom-silicon contracts: GOOG TPU multi-gen, META MTIA, ByteDance/Anthropic 3.5GW deal. Hock Tan named >$25B AI revenue trajectory FY26. VMware integration cash flow funds $7B+ annual buyback. Pre-earnings expectations 47% YoY rev / 52% EPS growth June 3.

  Unwind

  QCOM ASIC ByteDance win is exactly the named in-sourcing risk — second hyperscaler dual-sourcing announcement OR June 3 print missing custom-silicon $25B trajectory triggers further trim. Score below 60 floor flips to close.

  Catalyst

  Q2 earnings June 3 — custom-silicon revenue guide is the key

• MUMicron Technologycompute

  hold2.84%77
  flow acceleratingconf

  Funder

  Memory infrastructure bottleneck narrative inflecting — haiku flagged 5/27 'market narrative shifting toward memory chip infrastructure (SK Hynix, Micron at $1T valuations)'. HBM3e/HBM4 capacity sold out through 2026; HBM commitments from NVDA Blackwell, AMD MI350, Trainium3 anchor demand. Score 77 on watchlist, no policy items pressuring.

  Unwind

  HBM oversupply guide on next earnings, OR Samsung HBM3e qualification at NVDA breaks pricing, OR NAND ASP rolls over with broader memory cycle reversal.

  Catalyst

  Fiscal Q3 earnings late June — HBM mix / pricing commentary

• CCJCamecoenergy

  hold9.40%65
  flow steadyconf

  Funder

  Saskatchewan provincial backstop; Westinghouse 49% JV (Brookfield co-owner); long-term utility uranium contract book at $60+/lb floors with term-market spiking toward $150/lb per brief §5.2 (Kazatomprom 8Mlb output cut). IRA reactor incentives + 75 reactors under construction globally. Q1 +88% EPS growth. §5.3 commodity-producer hedge slot.

  Unwind

  Spot uranium below $60/lb sustained 90+ days with term market repricing OR Kazatomprom reversing supply discipline OR Westinghouse JV cash distributions deteriorating.

  Catalyst

  Q2 earnings (early August); term-market contract disclosures

• GEVGE Vernovaenergy

  trim6.04%-0.54pp63
  flow steadyconf

  Funder

  H-class turbine fleet 4M operating hours (128 units, 74GW), $150B+ backlog sold out through 2028, AI data-center grid pull-through. Norway GPFG added post-spin. IRA transmission/grid grants still flowing.

  Unwind

  Backlog book-to-bill <1.0 sustained two quarters OR wind-segment losses widening OR major H-class turbine reliability incident.

  Catalyst

  Q2 earnings late July — backlog and 2028+ slot allocation update

• TLNcompute

  hold4.73%
  flow acceleratingconf

  Funder

  AWS expanded PPA: 1,920 MW carbon-free nuclear from Susquehanna through 2042 (June 11 2025 SEC 8-K); SMR co-development and uprate exploration with AWS; Caithness CCGT acquisition (Jul 2025) immediately >40% FCF/share accretive in 2026. 2026 management EBITDA guide $1.75-2.05B / FCF $980M-$1.18B.

  Unwind

  AWS PPA renegotiation/cancellation, OR ERCOT/PJM regulatory cap on data-center power deals (named risk for the merchant-nuclear thesis), OR Susquehanna uprate denial by NRC.

  Catalyst

  Q2 earnings (early August); PJM capacity auction outcomes

• BEcompute

  hold3.78%
  flow acceleratingconf

  Funder

  Brookfield $5B AI data-center fuel-cell partnership (Oct 13 2025); Oracle on-site DC power agreement with warrant for 3.53M shares (Oct 28 2025 SEC 8-K); record product backlog $6B tied to AI infrastructure; capacity doubling to 2 GW annual by end-2026; prior agreements with Equinix, AEP, Quanta.

  Unwind

  Brookfield deal milestone slippage on first deployments OR product gross-margin breakdown sub-25% OR hyperscaler grid-interconnect timelines suddenly accelerate making on-site fuel cells uncompetitive.

  Catalyst

  Q2 earnings (early August) — Brookfield deployment milestones

• MPMP Materialsenergy

  hold4.03%
  flow acceleratingconf

  Funder

  DoD multi-billion public-private partnership: $400M Series A Preferred (closed Jul 11 2025) + up to $350M additional + $150M DoD loan for heavy rare earth separation; 10-year NdPr price floor commitment + 10-year magnet offtake for 10X Facility (10,000 MT/yr NdFeB). DoD is largest shareholder (~15%). Commodity-producer hedge slot per §5.3.

  Unwind

  DoD price-floor amendment downward OR magnet-offtake reduction OR Chinese rare-earth export normalization that collapses NdPr premium. Heavy-rare-earth separation project delay >18 months also triggers reassessment.

  Catalyst

  10X Facility groundbreaking milestones; FY26 DoD rare-earth strategy update

• SCCOSouthern Copperenergy

  hold4.03%63
  flow steadyconf

  Funder

  Copper supply deficit structural through grid electrification + AI DC build (~30% of new copper demand by 2030 per BloombergNEF). Tia Maria and Los Chancas project additions; Mexican gov dividend signal. Commodity-producer hedge slot per §5.3. Score 63 on watchlist.

  Unwind

  China property demand collapse OR Mexican mining-tax escalation OR copper sustained below $4/lb LME for 90 days.

  Catalyst

  Q2 earnings (late July) — Tia Maria permitting update

• KTOSKratos Defensedefense

  hold7.00%
  flow acceleratingconf

  Funder

  DoD MACH-TB 2.0 IDIQ prime: $1.45B ceiling 5-year (signed Jan 6 2025); DoD Industrial Base Project Helios hypersonic materials center $68.3M single-award (Oct 2025); USMC XQ-58A Valkyrie MUX TACAIR $34.8M mod (Jan 2025); C5ISR hardware $30M (Dec 2025); aviation training $65M (Feb 2026). Pure-play on Replicator/hypersonic flow per brief §5.3.

  Unwind

  MACH-TB task-order velocity below $200M/yr run-rate, OR DoD FY27 budget cuts hypersonic test infrastructure, OR Valkyrie program-of-record decision against KTOS prime.

  Catalyst

  FY27 PB submission (Feb 2027); Q2 earnings July with task-order pipeline

• HEIHEICOdefense

  hold5.60%68
  flow steadyconf

  Funder

  Defense aftermarket compounder — Mendelson family owners since 1957, 20%+ FCF CAGR sustained. Acquisition tape adding $1B+ rev annually. Wencor integration accretive. Score 68 on watchlist; NDAA mandatory funding + commercial aerospace MRO cycle dual-tailwind.

  Unwind

  Family ownership transition signal OR a >2 turn EBITDA multiple compression on Wencor-style M&A OR commercial MRO cycle reversal (RPK growth turning negative).

  Catalyst

  Q3 earnings late August; M&A announcements

• AVAVAeroVironmentdefense

  hold4.90%46
  flow acceleratingconf

  Funder

  Pure-play loitering munitions + autonomous systems per brief §7.1. DoD Replicator initiative budget allocation expanding (FY26 supplemental). NATO stockpile depletion in Ukraine driving multi-year backlog. BlueHalo merger (closed 2024) adds space/directed-energy. Switchblade-600 named Replicator vehicle.

  Unwind

  DoD Replicator budget formally reduced in FY27 PB request, OR gross margins sub-38% two consecutive quarters from supply-chain pass-through failure (brief §7.1 trigger), OR a major Switchblade competitor selection in NATO trial.

  Catalyst

  Q4 earnings (late June) — Replicator order disclosures

• LLYEli Lillybiology

  trim4.05%-0.95pp70
  flow steadyconf

  Funder

  Mounjaro/Zepbound franchise compounding internationally; retatrutide Phase 3 28% body-weight loss leapfrogs semaglutide; Curevo $1.5B + LimmaTech acquisitions extending vaccine/ID portfolio. Norway GPFG and large AM holders. GLP-1 ETF outperformance signal.

  Unwind

  Retatrutide CV outcomes trial setback OR US payer pushback on >$1k/mo pricing OR pipeline GLP-1 entrant from Roche/Pfizer with superior safety profile. Score sub-65 with confirmed share loss would trigger further trim.

  Catalyst

  Q2 earnings (early August); retatrutide CV outcomes readout

• VRTXVertex Pharmaceuticalsbiology

  hold4.05%76
  flow steadyconf

  Funder

  Only intact biology score (76, drift -2). Casgevy partnership with CRISPR expanding to pediatrics; suzetrigine non-opioid pain pipeline; CTX611 anticoagulant ($20B TAM). Self-funded cash runway insulates from 4.6% yield duration trap per brief §5.4. Pillar quality anchor.

  Unwind

  Suzetrigine commercial launch <$200M Y1, OR CF franchise YoY revenue growth turning negative, OR Casgevy uptake stuck below 100 patients/yr commercially.

  Catalyst

  Q2 earnings (late July) — suzetrigine launch trajectory

• NVONovo Nordiskbiology

  trim2.36%-2.82pp67
  flow softeningconf

  Funder

  Wegovy/Ozempic franchise still cash-generative; CagriSema next-gen pipeline; Novo Holdings sovereign-style ownership backstop. Norway GPFG and large EU pension funds hold. Generic exposure in India is real but cash-generative core intact.

  Unwind

  LLY US obesity share crossing 60% (named exit-invalidation trigger), OR CagriSema Phase 3 failure, OR CMS/payer mandated price compression >20%. Retatrutide's 28% weight-loss data is the active risk.

  Catalyst

  H2 CagriSema data; LLY retatrutide CV outcomes

• ARGXargenxbiology

  hold2.03%71
  flow steadyconf

  Funder

  Vyvgart franchise inflecting: gMG approval expanding to CIDP, MMN, SjD; multi-billion peak sales trajectory. Score 71 on watchlist. Self-sustaining commercial biotech that fits brief §5.4 commercial-stage-only constraint. Belgian ADR adds non-US weight.

  Unwind

  Vyvgart label expansion failure (CIDP, MMN, SjD readouts), OR biosimilar entry timeline accelerating, OR new entrant displacing Vyvgart in autoimmune space.

  Catalyst

  Q2 earnings (early August); Vyvgart label-expansion data readouts H2

Warnings

• stale_policy guard: TSM add → hold (delta zeroed)
• stale_policy guard: MU open → hold (delta zeroed)
• stale_policy guard: CCJ add → hold (delta zeroed)
• stale_policy guard: TLN open → hold (delta zeroed)
• stale_policy guard: BE open → hold (delta zeroed)
• stale_policy guard: MP open → hold (delta zeroed)
• stale_policy guard: SCCO open → hold (delta zeroed)
• stale_policy guard: KTOS open → hold (delta zeroed)
• stale_policy guard: HEI open → hold (delta zeroed)
• stale_policy guard: AVAV open → hold (delta zeroed)
• stale_policy guard: VRTX add → hold (delta zeroed)
• stale_policy guard: ARGX open → hold (delta zeroed)
• open_universe: KTOS already on watchlist — dropped
• open_universe: TLN score=44 < 60 — dropped
• open_universe: BE score=43 < 60 — dropped
• open_universe: MP already on watchlist — dropped
• open_universe: AVAV already on watchlist — dropped
• ledger stale (one or more positions had no last_price) — rebalance diffed against intent

Conviction-lock actions

No conviction-lock refusals or overrides this run.

Cost breakdown

Per-call cost computed from cost.js pricing constants (Opus 4.7, Sonnet 4.6, Haiku 4.5). Cache-read tokens billed at 10% of input. See Cost & ROI for the rolling 30-day ledger.